Rapid and accurate detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for the successful control of the current global COVID-19 pandemic. The real-time reverse transcription polymerase chain reaction (Real-time RT-PCR) is the most widely used detection technique. This research describes the development of two novel multiplex real-time RT-PCR kits, AccuPower ® COVID-19 Multiplex Real-Time RT-PCR Kit (NCVM) specifically designed for use with the ExiStation ™48 system (comprised of ExiPrep ™48 Dx and Exicycler ™96 by BIONEER, Korea) for sample RNA extraction and PCR detection, and AccuPower ® SARS-CoV-2 Multiplex Real-Time RT-PCR Kit (SCVM) designed to be compatible with manufacturers’ on-market PCR instruments. The limit of detection (LoD) of NCVM was 120 copies/mL and the LoD of the SCVM was 2 copies/μL for both the Pan-sarbecovirus gene and the SARS-CoV-2 gene. The AccuPower ® kits demonstrated high precision with no cross reactivity to other respiratory-related microorganisms. The clinical performance of AccuPower ® kits was evaluated using the following clinical samples: sputum and nasopharyngeal/oropharyngeal swab (NPS/OPS) samples. Overall agreement of the AccuPower ® kits with a Food and Drug Administration (FDA) approved emergency use authorized commercial kit (STANDARD™ M nCoV Real-Time Detection kit, SD BIOSENSOR, Korea) was above 95% (Cohen’s kappa coefficient ≥ 0.95), with a sensitivity of over 95%. The NPS/OPS specimen pooling experiment was conducted to verify the usability of AccuPower ® kits on pooled samples and the results showed greater than 90% agreement with individual NPS/OPS samples. The clinical performance of AccuPower ® kits with saliva samples was also compared with NPS/OPS samples and demonstrated over 95% agreement (Cohen’s kappa coefficient > 0.95). This study shows the BIONEER NCVM and SCVM assays are comparable with the current standard confirmation assay and are suitable for effective clinical management and control of SARS-CoV-2.
【초록키워드】 COVID-19, SARS-CoV-2, Saliva, coronavirus, COVID-19 pandemic, detection, drug, severe acute respiratory syndrome Coronavirus, sputum, RT-PCR, FDA, Food and Drug Administration, RNA extraction, polymerase chain reaction, sensitivity, PCR, Usability, Bioneer, Research, limit of detection, Rapid, Clinical management, microorganisms, reverse transcription, Swab, experiment, respiratory, real-time RT-PCR, multiplex, Cross reactivity, Emergency use, food, Chain Reaction, Real-Time Reverse Transcription Polymerase Chain Reaction, acute respiratory syndrome, Precision, acute respiratory syndrome coronavirus, Cohen’s kappa coefficient, acute respiratory syndrome coronavirus 2, specimen, market, nCoV, saliva samples, Kappa coefficient, SD Biosensor, effective, polymerase chain, greater, evaluated, approved, conducted, demonstrated, comparable, the SARS-CoV-2, 【제목키워드】 COVID-19, SARS-CoV-2, detection, RT-PCR, development, Sample,